139 related articles for article (PubMed ID: 11845814)
1. Muscle strength and tibolone: a randomised, double-blind, placebo-controlled trial.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
BJOG; 2002 Jan; 109(1):77-84. PubMed ID: 11845814
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal HRT and tibolone in relation to muscle strength and body composition.
Jacobsen DE; Samson MM; Kezic S; Verhaar HJ
Maturitas; 2007 Sep; 58(1):7-18. PubMed ID: 17576043
[TBL] [Abstract][Full Text] [Related]
3. The effects of tibolone in older postmenopausal women.
Cummings SR; Ettinger B; Delmas PD; Kenemans P; Stathopoulos V; Verweij P; Mol-Arts M; Kloosterboer L; Mosca L; Christiansen C; Bilezikian J; Kerzberg EM; Johnson S; Zanchetta J; Grobbee DE; Seifert W; Eastell R;
N Engl J Med; 2008 Aug; 359(7):697-708. PubMed ID: 18703472
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
[TBL] [Abstract][Full Text] [Related]
5. Tibolone does not affect muscle power and functional ability in healthy postmenopausal women.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
Clin Sci (Lond); 2002 Feb; 102(2):135-41. PubMed ID: 11834133
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses.
Lam PM; Cheung GW; Shek DT; Lee DT; Haines CJ; Chung TK
Menopause; 2004; 11(4):416-22. PubMed ID: 15243279
[TBL] [Abstract][Full Text] [Related]
7. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
8. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
[TBL] [Abstract][Full Text] [Related]
9. Tibolone improves depression in women through the menopause transition: A double-blind randomized controlled trial of adjunctive tibolone.
Kulkarni J; Gavrilidis E; Thomas N; Hudaib AR; Worsley R; Thew C; Bleeker C; Gurvich C
J Affect Disord; 2018 Aug; 236():88-92. PubMed ID: 29723767
[TBL] [Abstract][Full Text] [Related]
10. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
11. The influence of tibolone on quality of life in postmenopausal women.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
Maturitas; 2002 Jan; 41(1):35-43. PubMed ID: 11809341
[TBL] [Abstract][Full Text] [Related]
12. Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices: a 6-month, prospective, randomized, placebo-controlled, double-blind study.
Odabasi AR; Yuksel H; Kafkas S; Demircan S; Karul A; Kozaci D; Koseoglu K; Onur E
Adv Ther; 2006; 23(6):926-37. PubMed ID: 17276962
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial.
Morais-Socorro M; Cavalcanti MA; Martins R; Neto Francisco P; Rezende A; Azevedo G; Almeida M
Gynecol Endocrinol; 2012 Jun; 28(6):483-7. PubMed ID: 22132809
[TBL] [Abstract][Full Text] [Related]
14. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
15. The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women.
Meeuwsen IB; Samson MM; Duursma SA; Verhaar HJ
Endocrinology; 2001 Nov; 142(11):4813-7. PubMed ID: 11606448
[TBL] [Abstract][Full Text] [Related]
16. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women.
Egarter C; Topcuoglu A; Vogl S; Sator M
Acta Obstet Gynecol Scand; 2002 Jul; 81(7):649-53. PubMed ID: 12190840
[TBL] [Abstract][Full Text] [Related]
18. Vascular resistance of central retinal and ophthalmic arteries in postmenopausal women after use of tibolone.
de Souza MA; de Souza BM; Geber S
Menopause; 2012 Mar; 19(3):328-31. PubMed ID: 22042323
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
20. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
